Fig. 4
Reducing the content of UBR4 in MenSCs-EXO would alleviate its anti-fibrotic effect. The IUA model rats and IUA-EndoSCs were treated with EXO and EXOUBR4−, respectively. (A) Immunohistochemical staining of COL I and CTGF in the endometrium of IUA rats (Scale bar = 20 μm); (B) Western blot (left) and relative quantification (right) of COL I and CTGF in rat endometrium; (C) Immunofluorescence assays of COL I and CTGF (green) and DAPI was used to stain nuclei (Blue). (Scale bar = 50 μm); (D) Western blot (left) and relative quantification (right) of COL I and CTGF in IUA-EndoSCs before and after treatment. Data were mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001 for One Way ANOVA